AtriCure reports preliminary Q4 revenue $73.2M (+27% YoY), guides FY2022 $315-330M

AtriCure, Inc.

2021-FY EPS reported $1.09 revenue$274,329,000

Q4 2021 revenue ~$73.2M (+27% YoY); U.S. $61.2M (+29%), Intl $12.0M (+16% as reported).
Full year 2021 revenue $274.3M (+33% YoY); adj. EBITDA loss ~$10M, adj. loss per share ~$1.20.
Management guides FY2022 revenue $315-330M (15-20% growth over 2021), subject to pandemic uncertainty.
Preliminary, unaudited results – final audited results with GAAP reconciliation to follow in later release.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.